A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer

XIAOFENG CHEN,a,TIANZHU QIU,a,YINGWEI ZHU,b JING SUN,a,PING LI,a BIAO WANG,a PEINAN LIN,c XIAOMIN CAI,a XIAO HAN,a FENGQIAO ZHAO,a YONGQIANG SHU,a LIANGPENG CHANG,d HUA JIANG,b YANHONG GUa

Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of China; bDepartment of Oncology, The Affiliated Changzhou No. 2 People’s Hospital of Nanjing Medical University, Changzhou, People’s Republic of China; cDepartment of Oncology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, People’s Republic of China; dGeneplus-Beijing Institute, Beijing, People’s Republic of China

Contributed equally

Background. Apatinib, an oral vascular endothelial growth factor (VEGF) receptor-2 inhibitor, has been approved as third-line treatment for metastatic gastric cancer in China. The aim of this study was to evaluate the efficacy and safety of apatinib, in the treatment of patients with refractory metastatic colorectal cancer after failure of two or more lines of chemotherapy.

Methods. In this open-label, single-arm, phase II study, patients with histological documentation of adenocarcinoma of the colon or rectum were eligible if they had received at least two prior regimens of standard therapies including fluoropyrimidine, oxaliplatin, and irinotecan. These patients were treated with apatinib in a daily dose of 500 mg, p.o., in the third-line or higher setting. Capture sequencing was dynamically performed to identify somatic variants in circulating tumor DNA (ctDNA) with a panel of 1,021 cancer-related genes. The primary endpoint was progression-free survival (PFS) and the tumor response was determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Interim analysis was applied as predefined.

Results. From June 1, 2016 to December 31, 2017, 26 patients were enrolled. The median PFS of the whole group was 3.9 months (95% confidence interval [CI]: 2.1–5.9). The median overall survival (OS) was 7.9 months (95% CI: 4.6–10.1+). Patients with performance status (PS) 0–1 had longer PFS than those with PS 2 (4.17 months vs. 1.93 months, \( p = .0014 \)). Patients without liver metastasis also had longer PFS than those who had live metastasis (5.87 months vs. 3.33 months, \( p = .0274 \)). The common side effects of apatinib were hypertension, hand-foot syndrome, proteinuria, and diarrhea. The incidence of grade 3–4 hypertension, hand-foot syndrome, proteinuria, and diarrhea were 76.92%, 11.54%, 73.08%, and 23.08%, respectively. All of the patients received dose reduction because of adverse effect. Results of capture sequencing showed APC, TP53, and KRAS were most frequently mutant genes. ctDNA abundance increased before the radiographic assessment in ten patients.

Conclusion. Apatinib monotherapy showed promising efficiency for patients with refractory colorectal cancer, especially in patients with PS 0–1 or no liver metastasis. ctDNA abundance may be a predictor in serial monitoring of tumor load.

DISCUSSION

Here we report results from an open-label, single-arm, phase II study aiming to evaluate the efficacy and safety of

The Oncologist 2019;24:1–7 www.TheOncologist.com © AlphaMed Press 2019
apatinib as a salvage treatment for refractory metastatic colorectal cancer. To our knowledge, this is the first prospective clinical trial to investigate the safety and efficacy of apatinib in refractory metastatic colorectal cancer.

After two or more lines of prior chemotherapy, efficacy of apatinib in our study seemed to be comparable with other tyrosine kinase inhibitors reported in previous studies. However, compared with other studies, it seems that a higher incidence of adverse events of apatinib occurred. Firstly, patients in our study already have received multiple lines of chemotherapy before apatinib, with cumulative toxicity of previous drugs. Secondly, patients in our trial were required to record their blood pressure and other symptoms every day and were closely followed up by online tools; thus more adverse events could be recorded. In addition, the relatively small sample size of our study might impair the generalization of our conclusions. Patients with PS 0–1 had longer PFS than those with PS 2 in our study. A possible reason might be that patients with good physical status showed better tolerance of apatinib and thus benefited from it.

In metastatic colorectal cancer, ctDNA was reported to be an early marker of chemotherapy. Increasing ctDNA has been found ahead of radiographic detection of progression in 10 of 13 patients who had serial ctDNA detections in our study, suggesting that detection of ctDNA was associated with radiographic tumor burden. A challenge to the application of angiogenesis inhibitors is finding suitable biomarkers to select patients who are most likely to benefit from it. Here we sequenced a panel of 1,021 cancer-related genes in all patients. At least one mutation in ctDNA was detected in the baseline blood sample in 21 of 26 (81%) patients. The most frequently detected mutations were in APC (n = 16, 76%), TP53 (n = 12, 57%), KRAS (n = 9, 43%), PIK3CA (n = 5, 24%), INHBA (n = 4, 19%), ATR (n = 4, 14%), BRCA2 (n = 4, 14%), MTOR (n = 4, 14%), BRAF (n = 2, 10%), and BRD3 (n = 2, 10%). We performed a survival analysis to determine whether APC, TP53, or KRAS mutation was associated with PFS and OS; however, no statistical difference was found, potentially confounded by the small size of the study.

In conclusion, this study provides supporting evidence that apatinib exhibits efficacy for patients with refractory colorectal cancer, especially in patients with PS 0–1 or no liver metastasis. The common side effects of apatinib were hypertension, hand-foot syndrome, proteinuria, and diarrhea. Given that sample size was small in this study, further investigation in a larger population is required in the future.

**Trial Information**

| Disease                  | Colorectal cancer          |
|--------------------------|-----------------------------|
| Disease                  | Advanced cancer             |
| Stage of Disease/Treatment| Metastatic/advanced         |
| Prior Therapy            | More than two prior regimens|
| Type of Study – 1        | Phase II                    |
| Type of Study – 2        | Single arm                  |
| Primary Endpoint         | Progression-free survival   |
| Investigator’s Analysis  | Active and should be pursued further |

**Drug Information**

| Drug 1 | Generics/Working Name | Apatinib |
|--------|------------------------|----------|
|        | Trade Name             | Aitan    |
Company Name: Jiangsu HengRui Medicine Co., Ltd.
Drug Type: Small molecule
Drug Class: Angiogenesis - VEGF
Dose: 500 milligrams (mg) per flat dose
Route: Oral (po)
Schedule of Administration: 28-day cycle

**PATIENT CHARACTERISTICS**

| Number of Patients, Male | 16 |
|--------------------------|----|
| Number of Patients, Female | 10 |
| Stage | IV |
| Age | Median (range): 57 (28–75) years |
| Number of Prior Systemic Therapies | Median (range): 4 (3–6) |
| Performance Status: ECOG | 0 — 2 |
| | 1 — 18 |
| | 2 — 6 |
| | 3 — 0 |
| | Unknown — 0 |

**Cancer Types or Histologic Subtypes**

| Right or transverse colon | 6 |
| Left colon | 10 |
| Rectum | 10 |

**PRIMARY ASSESSMENT METHOD FOR PHASE II APATINIB**

| Title | Total patient population |
|-------|--------------------------|
| Number of Patients Screened | 26 |
| Number of Patients Enrolled | 26 |
| Number of Patients Evaluable for Toxicity | 26 |
| Number of Patients Evaluated for Efficacy | 26 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | n = 0 (0%) |
| Response Assessment PR | n = 0 (0%) |
| Response Assessment SD | n = 14 (23%) |
| Response Assessment PD | n = 9 (69%) |
| Response Assessment OTHER | n = 3 (8%) |
| (Median) Duration Assessments PFS | 3.9 months |
| (Median) Duration Assessments OS | 7.9 months |

Waterfall plot showing the percentage of tumor diameter change at time of best response. Only 25 cases were recorded because one patient died before the first evaluation.
ADVERSE EVENTS

All Cycles

| Name                                      | NC/NA, % | Grade 1, % | Grade 2, % | Grade 3, % | Grade 4, % | Grade 5, % | All grades, % |
|-------------------------------------------|----------|------------|------------|------------|------------|------------|---------------|
| Hypertension                              | 0        | 0          | 23         | 77         | 0          | 0          | 100           |
| Palmar-plantar erythrodysesthesia syndrome | 0        | 23         | 65         | 12         | 0          | 0          | 100           |
| Proteinuria                               | 4        | 0          | 23         | 73         | 0          | 0          | 96            |
| Diarrhea                                  | 23       | 4          | 50         | 23         | 0          | 0          | 77            |
| White blood cell decreased                | 73       | 12         | 15         | 0          | 0          | 0          | 27            |
| Neutrophil count decreased                | 73       | 23         | 4          | 0          | 0          | 0          | 27            |
| Platelet count decreased                  | 73       | 8          | 15         | 4          | 0          | 0          | 27            |
| Anemia                                    | 73       | 27         | 0          | 0          | 0          | 0          | 27            |
| Alanine aminotransferase increased        | 54       | 42         | 4          | 0          | 0          | 0          | 46            |
| Blood bilirubin increased                | 65       | 31         | 4          | 0          | 0          | 0          | 35            |
| Creatinine increased                      | 88       | 12         | 0          | 0          | 0          | 0          | 12            |
| Alkaline phosphatase increased            | 61       | 23         | 8          | 8          | 0          | 0          | 39            |
| Hypothyroidism                            | 77       | 15         | 4          | 4          | 0          | 0          | 23            |

Adverse Events Legend
Toxicities occurring in every patient over the entire duration on study. Abbreviation: NC/NA, no change from baseline/no adverse event.

ASSESSMENT, ANALYSIS, AND DISCUSSION

Completion
Study completed

Investigator’s Assessment
Active and should be pursued further

Here we reported results from an open-label, single-arm, phase II study aiming to evaluate the efficacy and safety of apatinib as a salvage treatment for refractory metastatic colorectal cancer (mCRC). A total of 54 participants were planned to be enrolled. From June 1, 2016 to December 31, 2017, 26 patients were enrolled. The median PFS was 3.9 months and median OS was 7.9 months. As shown in Figure 1, patients with performance status (PS) 0–1 had longer PFS than those with PS 2 (4.17 months vs. 1.93 months, p = .0014). As shown in Figure 2, patients without liver metastasis also had longer PFS than those who had live metastasis (5.87 months vs. 3.33 months, p = .0274).

Apatinib has demonstrated encouraging anticancer activity across a broad range of malignancies, including epithelial ovarian cancer [1], glioma [2], breast cancer [3, 4], gastric cancer [5, 6], and hepatocellular carcinoma [7]. There are still another 181 undergoing studies registered at ClinicalTrials.gov (https://www.clinicaltrials.gov). Two retrospective results about apatinib in advanced mCRC had been reported. Recently a real-world retrospective study explored the apatinib used in mCRC [8]. Median progression-free survival (PFS) of this study was 3.82 months, and median overall survival (OS) was not reached. Another pilot study also suggested that apatinib was active as a third-line treatment of refractory mCRC with PFS of 4.8 months and OS of 10.1 months [9]. Although there were data from pilot and real-world retrospective studies of apatinib, this is the first prospective clinical trial to investigate the safety and efficacy of apatinib in refractory metastatic colorectal cancer to our knowledge.

After two or more lines of prior chemotherapy, the efficacy of apatinib in our study seemed to be comparable with other tyrosine kinase inhibitors (TKIs) reported in previous studies. The CORRECT [10] and CONCUR [11] trials compared regorafenib with placebo among patients with mCRC who had received at least two prior chemotherapy regimens. In the CORRECT study, median PFS and OS were 1.9 months and 6.4 months for the regorafenib group and 3.2 months and 8.8 months, respectively, in the CONCUR study. The FRESCO study [12] evaluated efficacy of oral fruquintinib as third-line or later therapy among patients with mCRC, in which the median PFS and median OS were 3.71 and 9.30 months. In our study, apatinib conferred a 3.9-month median PFS and 7.9-month median OS, which is comparable to that of regorafenib and fruquintinib. The objective response rate was approximately 1%–4.7% in trials of fruquintinib and regorafenib in mCRC [2–4]. No objective responses were observed in our trial. The relatively small sample size of our study might be the possible reason. Objective response might be observed if more patients were included in our trial.

Regarding to the safety of apatinib, hypertension, hand-foot syndrome, proteinuria, and diarrhea are the most common adverse events in our study. These events are also well-known, common adverse events in most studies of small-molecule vascular endothelial growth factor receptor (VEGFR) TKI [6, 13]. VEGFR TKI could reduce blood flow and vessel patency, which were noted not in only tumor cells, but also in normal vasculature, particularly a loss of endothelial cells fenestrae in renal glomeruli and several endocrine
organs [14]. Besides, anti-VEGF-A/VEGFR therapy also contributed to constriction of the feeder arteries supplying tumors, leading to reduced downstream blood flow and systemic hypertension [14]. These findings provided an explanation for some side effects of VEGFR TKI. Compared with other studies, it seems that a higher incidence of adverse events of apatinib occurred in our study. Firstly, patients in our study already have received multiple lines of chemotherapy before apatinib, with cumulative toxicity of previous drugs. Secondly, patients in our trial were required to record their blood pressure and other symptoms every day and were closely followed-up by online tools; thus more adverse events could be recorded. In addition, the relatively small sample size of our study might impair the generalization of our conclusions. All the patients received dose reduction because of adverse events, indicating that a dose of 500 mg each day is unacceptable in heavily pretreated patients with colorectal cancer, and the toxicity administration is very important. Patients with performance status (PS) 0–1 had longer PFS than those with PS 2 in our study. The possible reason might be that patients with good physical status showed better tolerance of apatinib and thus benefit from it.

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream, acting as a surrogate for tumor biopsy that can be detected in patients with cancer by identifying genomic aberrations. Recent studies showed that quantitative ctDNA dynamics could predict therapeutic efficacy before tumor response was assessed by imaging or clinical symptoms [15–17]. In metastatic colorectal cancer, ctDNA was reported to be an early marker of chemotherapy [18, 19]. In our study, increasing ctDNA has been found ahead of radiographic detection in 10 of 13 patients who had serial ctDNA detected, suggesting that detection of ctDNA was associated with radiographic tumor burden, which is consistent with previous studies.

A challenge to the application of angiogenesis inhibitors is finding suitable biomarkers to select patients who are most likely to benefit from it. Unfortunately, there has been no success in identifying biomarkers for any antiangiogenic drugs. As we know, VEGF signal transduction plays an important role in angiogenesis. It is worth mentioning that therapeutic intervention by blocking VEGF signal transduction occurs not only in tumor-associated blood vessels but also in nonmalignant endothelial cells and tumor microenvironment [20, 21]. Tumor microenvironment was considered as potential source of clinical biomarkers [22]. Circulating endothelial cells have been correlated with prognosis in several tumors and with response to bevacizumab in colorectal cancer [23–25]. Here we analyzed a panel of 1,021 cancer-related gene in all of the patients. The mutations detected in baseline ctDNA were showed in Figure 3A, which is consistent with MSK-IMPACT profiles (Fig. 3B). We assessed whether APC, TP53, or KRAS mutation was associated with PFS and OS. Unfortunately, no positive results were found. On one hand, this study was subject to limitations of small sample size; on the other hand, as we mentioned above, antiangiogenic therapies act at least in part on vascular microenvironment rather than on tumor cells, making it more difficult to identify a biomarker in circulating tumor DNA.

It should be noted that there were still some limitations in our study, including small size, possible information bias, and lack of a control group. Multicenter randomized controlled double-blind clinical trials and further follow-up are expected in the future.

In conclusion, this study provides supporting evidence that apatinib exhibits efficacy for patients with refractory colorectal cancer, especially in patients with PS 0–1 or no liver metastasis. The common side effects of apatinib were hypertension, hand-foot syndrome, proteinuria, and diarrhea. Given that sample size was small in this study, the efficacy and safety of apatinib in mCRC requires further investigation in a larger population.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (grant 81572389), Jiangsu 333 Project (grant BRA2016517), Jiangsu Province Key Medical Talents (grant ZDRCA2016026), and the Advanced Health Talent of Six-One Project of Jiangsu Province (grant LGY2017069).

DISCLOSURES
The authors indicated no financial relationships.

REFERENCES

1. Miao M, Deng G, Luo S et al. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecol Oncol 2018;148:286–290.
2. Wang L, Liang L, Yang T et al. A pilot clinical study of apatinib plus irinotecan in patients with recurrent high-grade glioma: Clinical trial/experimental study. Medicine 2017;96:e0953.
3. Hu X, Cao J, Hu W et al. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer 2014;14:820.
4. Hu X, Zhang J, Xu B et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer 2014;135:1961–1969.
5. Huang L, Wei Y, Shen S et al. Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients. Oncotarget 2017;8:29346–29354.
6. Li J, Qin S, Xu J et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: Results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013;31:3219–3225.
7. Lu W, Jin XL, Yang C et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate- and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther 2017;18:433–438.
8. Gou M, Si H, Zhang Y et al. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: A real-world retrospective study. Sci Rep 2018;8:4602.
9. Liang L, Wang L, Zhu P et al. A pilot study of apatinib as third-line treatment in patients with heavily treated metastatic colorectal cancer. Clin Colorect Cancer 2018;17:e443–e444.
10. Grotthe A, Van Cutsen E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303–312.
11. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619–629.
12. Li J, Qin S, Xu RH et al. Effect of fruzolinate vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: The
FRESCO randomized clinical trial. JAMA 2018;319: 2486–2496.

13. Li J, Zhao X, Chen L et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010;10:529.

14. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: Reassessing the target. Cancer Res 2012;72:1909–1919

15. Dawson SJ, Tsui DW, Murtaza M et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368:1199–1209.

16. Mok T, Wu YL, Lee JS et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015; 21:3196–3203.

17. Garcia-Murillas I, Schiavon G, Weigelt B et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 2015; 7:302ra133.

18. Tie J, Kinde I, Wang Y et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol 2015;26:1715–1722.

19. Garlan F, Laurent-Puig P, Sefrioui D et al. Early evaluation of circulating tumor DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL study). Clin Cancer Res 2017;23: 5416–5425.

20. Lacal PM, Graziani G. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Pharmacol Res 2018; 136:97–107.

21. Romero-Laorden N, Doger B, Hernandez M et al. Predictive biomarker candidates to delineate efficacy of antiangiogenic treatment in renal cell carcinoma. Clin Transl Oncol 2016; 18:1–8.

22. Genova C, Rijavec E, Grossi F. Tumor microenvironment as a potential source of clinical biomarkers in non-small cell lung cancer: Can we use enemy territory at our advantage? J Thorac Dis 2017;9:4300–4304.

23. Sakamori Y, Masago K, Ohmori K et al. Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small-cell lung cancer. Cancer Sci 2012;103:1065–1070.

24. Jain S, Ward MM, O’Loughlin J et al. Incremental increase in VEGFR1(+) hematopoietic progenitor cells and VEGFR2(+) endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients. Breast Cancer Res Treat 2012;132:235–242.

25. Manzoni M, Mariucci S, Delfanti S et al. Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol 2012;138: 1187–1196.
Figure 3. Mutations detected. Mutations detected in baseline (A) and mutations of baseline circulating tumor DNA and MSK integrated mutation profiling of actionable cancer targets (IMPACT) profiles (B). Abbreviations: CNV, copy number variation; ECOG, Eastern Cooperative Oncology Group; MSK, Memorial Sloan Kettering.